Cellect Biotechnology Ltd

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The company was founded on March 5, 2018 and is headquartered in Kefar Sava, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and distribution date for the contingent value rights (the “CVRs”) to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the “Merger”) and the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd., to EnCellX, Inc., a privately held company based in San Diego, CA (the “Share Transfer”).

Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

Aterian

Biomerica

Marin Software

Progenity

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) and AMC Entertainment Holdings Inc (NYSE: AMC), two stocks that attracted strong interest and saw shares spike. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays

Cellect Biotechnology Ltd (NASDAQ: APOP) is trading higher Monday after the company announced shareholder approval of the strategic merger with Quoin Pharmaceuticals. Approximately 99% of the votes were in favor of approving the proposal.

Why Cellect Biotechnology Shares Are Rising Today

Cellect Biotechnology Ltd (NASDAQ: APOP) shareholders approved the previously announced strategic merger agreement with Quoin Pharmaceuticals, the company said in a press release on Monday. Shares of the Israel-headquartered firm jumped about 50% this morning.

Here's why Cellect Biotechnology shares are up 50% on Monday

Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA.

Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

The stock price of Cellect Biotechnology Ltd (NASDAQ: APOP) increased by over 70% pre-market. This is why it happened.

APOP Stock: Over 70% Increase Pre-Market Explanation

Cellect Biotechnology Ltd (NASDAQ: APOP) announced the first ApoGraft transplantation in a Leukemia patient in a clinical trial in the U.S.  ApoGraft is designed to prevent graft-versus-host disease (GVHD) following bone marrow transplantation.

See Why Cellect Biotechnology Stock Is Soaring During Premarket Friday

Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX

Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter

Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

The shares of Cellect Biotechnology Ltd (NASDAQ: APOP) increased by over 10% pre-market. This is why it happened.

Cellect Biotechnology Shares Increase Over 10% Pre-Market: Why It Happened

Special General Meeting of Shareholders Scheduled for September 19, 2021

The Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

Acasti Pharma

Aerpio Pharmaceuticals Inc

Check-Cap

Seelos Therapeutics

SCWorx Corp

Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist

Alset EHome International

Clover Health Investments

Digital Brands Group Inc

Orphazyme A/S

Short squeeze stocks have been targeted quite a bit lately as retail traders tackle them in an effort to push out hedge funds. The post Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop

Evofem Biosciences Inc

9F Inc - ADR

3 big gaining penny stocks today; are they worth it? The post These Penny Stocks Are Up Big Today, Worth It or Not?

These Penny Stocks Are Up Big Today, Worth It or Not?

Cellect Biotechnology Ltd (NASDAQ: APOP) has filed a registration statement with the SEC in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals Inc. See the SEC registration document here.

Why Are Cellect Biotechnology (APOP) Shares Surging Today?

The stock price of Cellect Biotechnology Ltd (NASDAQ: APOP) increased by over 55% pre-market. This is why it happened.

APOP Stock Price Increases Over 55% Pre-Market: Why It Happened

Transaction Expected to Close in the 2021 Third Quarter Transaction Expected to Close in the 2021 Third Quarter

Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

Borr Drilling Ltd

Second Sight Medical Products

These penny stocks moved in early morning trading; will you add them to your watchlist? The post Are These Penny Stocks The Biggest Morning Movers?

Are These Penny Stocks The Biggest Morning Movers?

Atossa Genetics

22nd Century Group

Looking for the best penny stocks in May 2021? Check these 5 out The post 5 Hot Penny Stocks To Buy?

5 Hot Penny Stocks To Buy? Check These Out For May 2021

CKX Lands

Cue Biopharma

Eltek

SemiLEDs

Obalon Therapeutics

Precipio

PolarityTE Inc

Protagenic Therapeutics

Regional Health Properties

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on InvestorPlace.

Market Update: The 10 Most Volatile Stocks Today

Cellect Biotechnology Ltd (NASDAQ: APOP) has announced data from the Phase 1/2 study in Israel evaluating ApoGraft technology for Graft versus Host Disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted on time.

Cellect Bio's ApoGraft Therapy Is Safe, Tolerable In GvHD Study

TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

F-Star Therapeutics Inc

Immutep Ltd

ProQR Therapeutics

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

ProQR Therapeutics NV (NASDAQ: PRQR) shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially. ProQR is a biopharmaceutical company that develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Why PRQR Stock And APOP Stock Are Popping Off Today

APOP stock holders are getting a 1:3 ratio of shares in the tie-up deal. The merger brings together Cellect's stem cell tech with Quoin's rare and orphan diseases focus.

News for Cellect Biotechnology Ltd Stock (APOP)